Get the Stockscreener App
4.20
3.67%
-0.16
After Hours:
4.25
0.05
+1.19%
Cingulate Inc stock is traded at $4.20, with a volume of 190.91K.
It is down -3.67% in the last 24 hours and down -3.89% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
See More
Previous Close:
$4.36
Open:
$4.34
24h Volume:
190.91K
Relative Volume:
0.62
Market Cap:
$12.91M
Revenue:
-
Net Income/Loss:
$-21.21M
P/E Ratio:
-2.4852
EPS:
-1.69
Net Cash Flow:
$-16.86M
1W Performance:
-6.25%
1M Performance:
-3.89%
6M Performance:
-55.62%
1Y Performance:
-94.88%
1-Day Range:
$3.94
$4.35
1-Week Range:
$3.94
$4.90
52-Week Range:
$1.8001
$152.40
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.20 | 12.91M | 0 | -21.21M | -16.86M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
Cingulate (NASDAQ:CING) Upgraded at Maxim Group - Defense World
U.S. Stock market top gainers: Binah Capital Group gains +107.02%, Aligos Therapeutics surges by 42.84% in mid day trading - Business Upturn
Cingulate Inc. Announces Third Quarter Financial Results and Clinical Update - Defense World
Cingulate Inc (CING) Quarterly 10-Q Report - Quartz
CINGCingulate Inc. Latest Stock News & Market Updates - StockTitan
Cingulate reports Q3 net loss $3.2M vs. $5.98M last year - TipRanks
Cingulate Reports Third Quarter 2024 Financial - GlobeNewswire
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market - StockTitan
Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show - The Manila Times
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show - GlobeNewswire
Cingulate secures funding to extend operations into Q2 2025 By Investing.com - Investing.com South Africa
SEC Form 424B3 filed by Cingulate Inc. - Quantisnow
Cingulate secures funding to extend operations into Q2 2025 - Investing.com India
Cingulate Inc. CEO faces domestic battery charge - Investing.com India
Cingulate Inc. CEO faces domestic battery charge By Investing.com - Investing.com South Africa
KC-area public company CEO faces charges for aggravated domestic battery - The Business Journals
Cingulate files to sell 1.5M shares of common stock for holders - MSN
Will Ciena's New 1.6 Tb/s Coherent Pluggable Solution Drive Top Line? - Zacks Investment Research
Concentrix Corp (CNXC) Q3 2024: Everything You Need to Know Ahea - GuruFocus.com
Cettire shares skyrocket - Finance News Network
Cettire gets auditor’s tick of approval, adding $247m to valuation - The Australian Financial Review
Stock of the day: Cettire - IG
Ciena Stock Goes to Buy From Sell at Citi. Here’s Why. - Barron's
Why Ciena Stock Popped 5% on Monday - The Motley Fool
Double-Upgrade Pushes Ciena Stock Near Record Highs - Schaeffers Research
Citi upgrades Ciena, shares rise in pre-market trade By Investing.com - Investing.com Canada
9 Analysts Assess Ciena: What You Need To Know - Benzinga
Ciena Unveils 1.6 Tb/s Coherent Pluggable Solution for Hyperscale Cloud Providers' Capacity Surge - Marketscreener.com
Ciena's stock rises after Citi double upgrades to Buy (NYSE:CIEN) - Seeking Alpha
Citi sees growth potential for Ciena stock as inventory challenges ease - Investing.com Australia
Ciena Co. (NYSE:CIEN) Shares Sold by Thrivent Financial for Lutherans - Defense World
KC-area pharmaceutical company starts its last trial before seeking FDA approval - The Business Journals
CING’s Market Whiplash: -94.12% YTD Decline, 192.68% Rise in 30 Days - The InvestChronicle
Cingulate Inc (CING)’s stock decline to 5.40 per share - US Post News
Where are the Opportunities in (CING) - Stock Traders Daily
Cingulate Inc (CING) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Cingulate Inc: Executive Pay Restored, Funding Up, FDA Study Launched - TipRanks
Cingulate initiates final study for ADHD asset CTx-1301 - TipRanks
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301 - GlobeNewswire
Market Insights: Cingulate Inc (CING)’s Notable Gain of 19.45, Closing at 6.51 - The Dwinnex
Cingulate regains Nasdaq compliance with bid price - Investing.com
Cingulate Shares Are Trading By More Than 200% Friday: What You Need To Know - MSN
Stocks of Cingulate Inc (CING) are poised to climb above their peers - SETE News
September 04, 2024 09:00 AM, Eastern - Nasdaq
Was there any good news for Cingulate Inc (CING) stock in the last session? - US Post News
Cingulate Inc. expands at-the-market offering by $3.87 million - Investing.com
Financial Health Report: Cingulate Inc (CING)’s Ratios Tell a Tale - The Dwinnex
CING’s 2023 Market Dance: Down -91.41% – Time to Invest? - The InvestChronicle
What's Going On With Cingulate Shares Recently? - MSN
Take off with Cingulate Inc (CING): Get ready for trading - SETE News
Cingulate Inc. reports increased share count following capital-raising - Investing.com
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):